ID   H69/BCNU
AC   CVCL_0B21
DR   cancercelllines; CVCL_0B21
DR   Wikidata; Q54872200
RX   PubMed=9062409;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:3423; Carmustine (BCNU).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1579 ! NCI-H69
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=9062409; DOI=10.1038/bjc.1997.154;
RA   Jensen P.B., Holm B., Sorensen M., Christensen I.J., Sehested M.;
RT   "In vitro cross-resistance and collateral sensitivity in seven
RT   resistant small-cell lung cancer cell lines: preclinical
RT   identification of suitable drug partners to taxotere, taxol, topotecan
RT   and gemcitabin.";
RL   Br. J. Cancer 75:869-877(1997).
//